Biotech · Private company
Hutchmed
Track this companyFree. Adds Hutchmed to your Dealase workspace and tells you when its record changes.
Clinical trials213 recruiting or active
Pipeline programs29From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline29
- FruquintinibPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-A251Phase 2 · Solid Tumors, AdultClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-A580Phase 2 · Solid Tumors, AdultClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-A830Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- surufatinibPhase 2 · TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SurufatinibPhase 2 · Neuroendocrine TumoursClinicalTrials.gov · fetched Nov 12, 2026
- Surufatinib and Tislelizumab _ Part 1Phase 2 · Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Surufatinib and Tislelizumab _ Part 2Phase 2 · Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Surufatinib in combination with GemcitabinePhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Dabigatran EtexilatePhase 1 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Fluconazole 400 mgPhase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- FruquintinibPhase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- FruquintinibPhase 1 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- FruquintinibPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-306Phase 1 · Isocitrate Dehydrogenase Gene MutationClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-523Phase 1 · Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-523Phase 1 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-523Phase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-689Phase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- HMPL-760Phase 1 · CLL/SLLClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Itraconazole 200 mgPhase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RabeprazolePhase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Rabeprazole 40 mgPhase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RifampinPhase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Rifampin 600 mgPhase 1 · Relapsed or Refractory LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RosuvastatinPhase 1 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- SurufatinibNeuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials21
- HMPL-A830 in Solid TumorsPHASE1_PHASE2 · RECRUITING · started Sep 24, 2026ClinicalTrials.gov NCT07718581 · fetched Nov 12, 2026
- HMPL-A580 in Participants With Advanced or Metastatic Solid TumorPHASE1_PHASE2 · RECRUITING · started Mar 4, 2026ClinicalTrials.gov NCT07396584 · fetched Nov 12, 2026
- A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid TumorsPHASE1_PHASE2 · RECRUITING · started Dec 16, 2025ClinicalTrials.gov NCT07228247 · fetched Nov 12, 2026
- The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)PHASE1 · WITHDRAWN · started Apr 2, 2024ClinicalTrials.gov NCT06291415 · fetched Nov 12, 2026
- HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer StudyPHASE1 · COMPLETED · started Nov 4, 2022ClinicalTrials.gov NCT05720767 · fetched Nov 12, 2026
- HMPL-523 Food Effect and Proton Pump Inhibitor StudyPHASE1 · COMPLETED · started Jul 13, 2022ClinicalTrials.gov NCT05571787 · fetched Nov 12, 2026
- HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPIPHASE1 · COMPLETED · started Jun 1, 2022ClinicalTrials.gov NCT05602597 · fetched Nov 12, 2026
- Fruquintinib Renal Impairment StudyPHASE1 · COMPLETED · started Mar 11, 2022ClinicalTrials.gov NCT05216354 · fetched Nov 12, 2026
- Fruquintinib Hepatic Impairment StudyPHASE1 · COMPLETED · started Mar 11, 2022ClinicalTrials.gov NCT05216367 · fetched Nov 12, 2026
- Fruquintinib DDI Study With P-gp and BCRP SubstratesPHASE1 · COMPLETED · started Mar 2, 2022ClinicalTrials.gov NCT05368805 · fetched Nov 12, 2026
- HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHLPHASE1 · WITHDRAWN · started Feb 15, 2022ClinicalTrials.gov NCT05176691 · fetched Nov 12, 2026
- A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid TumorsPHASE1_PHASE2 · COMPLETED · started Nov 30, 2021ClinicalTrials.gov NCT05093322 · fetched Nov 12, 2026
- Open-Label Surufatinib in European Patients With NETPHASE2 · TERMINATED · started Aug 13, 2021ClinicalTrials.gov NCT04579679 · fetched Nov 12, 2026
- A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsPHASE1_PHASE2 · TERMINATED · started Aug 9, 2021ClinicalTrials.gov NCT04577963 · fetched Nov 12, 2026
- A Study of HMPL-306 in Advanced Hematological Malignancies With mIDHPHASE1 · TERMINATED · started Apr 12, 2021ClinicalTrials.gov NCT04764474 · fetched Nov 12, 2026
- Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsPHASE1_PHASE2 · TERMINATED · started Mar 5, 2021ClinicalTrials.gov NCT04579757 · fetched Nov 12, 2026
- A Study of HMPL-306 in Advanced Solid Tumors With IDH MutationsPHASE1 · TERMINATED · started Feb 28, 2021ClinicalTrials.gov NCT04762602 · fetched Nov 12, 2026
- An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaPHASE1 · TERMINATED · started Sep 26, 2019ClinicalTrials.gov NCT03779113 · fetched Nov 12, 2026
- Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With LymphomasPHASE1 · TERMINATED · started Aug 26, 2019ClinicalTrials.gov NCT03786926 · fetched Nov 12, 2026
- A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02549937 · fetched Nov 12, 2026
- Expanded Access Program of SurufatinibNO_LONGER_AVAILABLEClinicalTrials.gov NCT04814732 · fetched Nov 12, 2026